Rexulti and Attention deficit hyperactivity disorder - a phase IV clinical study of FDA data

Summary:

Attention deficit hyperactivity disorder is reported as a side effect among people who take Rexulti (brexpiprazole), especially for people who are female, 40-49 old, also take Vitamin D3, and have Narcolepsy.

The phase IV clinical study analyzes which people have Attention deficit hyperactivity disorder when taking Rexulti. It is created by eHealthMe based on reports of 13,206 people who have side effects when taking Rexulti from the FDA, and is updated regularly.

What is Rexulti?

Rexulti has active ingredients of brexpiprazole. It is often used in major depression. eHealthMe is studying from 13,394 Rexulti users. Check the latest studies of Rexulti.

What is Attention deficit hyperactivity disorder?

Attention deficit hyperactivity disorder (a chronic condition including attention difficulty, hyperactivity, and impulsiveness) is found to be associated with 608 drugs and 1,395 conditions by eHealthMe. Check the latest studies of Attention deficit hyperactivity disorder.

eHealtheMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 13, 2026

13,206 people reported to have side effects when taking Rexulti.
Among them, 14 people (0.11%) have Attention deficit hyperactivity disorder.

Could Rexulti cause Attention deficit hyperactivity disorder?

Among these 14 people:

What is the gender of people who have Attention deficit hyperactivity disorder when taking Rexulti? *

female: 92.86 %
male: 7.14 %

What is the age of people who have Attention deficit hyperactivity disorder when taking Rexulti? *

What are other drugs people take besides Rexulti? *

What are other side effects people have besides Attention deficit hyperactivity disorder? *

Joint Pain: 4 people, 28.57%
Skin Infection: 4 people, 28.57%
Influenza Like Illness: 4 people, 28.57%
Infusion Site Swelling: 4 people, 28.57%
Localised Infection (infection at the single location): 4 people, 28.57%
Neuralgia (pain in one or more nerves): 4 people, 28.57%
Bronchitis (inflammation of the mucous membrane in the bronchial tubes): 4 people, 28.57%
Autoimmune Disorder (a condition in which the immune system attacks the body's normal substances and tissue): 4 people, 28.57%
Pain: 4 people, 28.57%
Abscess Oral (abscess in the mouth): 4 people, 28.57%

What are the existing conditions these people have? *

Narcolepsy (brain's inability to regulate sleep-wake cycles normally): 6 people, 42.86%
Cataplexy (loss of muscle tone accompanied by full conscious awareness): 5 people, 35.71%
Immunodeficiency Common Variable: 4 people, 28.57%
Drowsiness: 3 people, 21.43%
Weight Decreased: 1 person, 7.14%
Schizoaffective Disorder (a mental disorder characterized by disordered thought): 1 person, 7.14%
Panic Disorder: 1 person, 7.14%
Generalized Anxiety Disorder (excessive, uncontrollable, unexplained and often irrational worry): 1 person, 7.14%

* Approximation only. Some reports may have incomplete information.

Do you take Rexulti and have Attention deficit hyperactivity disorder?

- Check whether Attention deficit hyperactivity disorder is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Rexulti:

Rexulti (13,394 reports)

Attention deficit hyperactivity disorder treatments and more:

Attention deficit hyperactivity disorder (120,340 reports)

How severe was Attention deficit hyperactivity disorder and when was it recovered:

Attention deficit hyperactivity disorder in Rexulti

Expand to all the drugs that have ingredients of brexpiprazole:

Attention deficit hyperactivity disorder and drugs with ingredients of brexpiprazole (15 reports)

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Rexulti:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Attention deficit hyperactivity disorder:

Attention deficit hyperactivity disorder (608 drugs)

Browse all the conditions that are associated with Attention deficit hyperactivity disorder:

Attention deficit hyperactivity disorder (1,395 conditions)

Related publications that referenced our studies

Coskun M, Adak I, "Excessive and frequent menstrual bleeding with methylphenidate in an adolescent girl with attention-deficit hyperactivity disorder", Journal of clinical psychopharmacology, 2017 Oct .
Lufi D, Bucherman M, Akita M, Cohen R, Sibani C, "The effect of methylphenidate on speech patterns of children with attention deficit disorder", Journal of Behavioral Health, 2012 Jan .
Coskun M, Adak I, "Excessive and frequent menstrual bleeding with methylphenidate in an adolescent girl with attention-deficit hyperactivity disorder", Journal of clinical psychopharmacology, 2017 Oct .
Lufi D, Bucherman M, Akita M, Cohen R, Sibani C, "The effect of methylphenidate on speech patterns of children with attention deficit disorder", Journal of Behavioral Health, 2012 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on brexpiprazole (the active ingredients of Rexulti) and Rexulti (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.